{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schwarze JK"],"funding":["Stichting Tegen Kanker","Oncology Center Vrije Universiteit Brussel","Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society"],"pagination":["e005141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9486335"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(9)"],"pubmed_abstract":["<h4>Background</h4>Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)<sup>+</sup> / CD141 (BDCA-3)<sup>+</sup> myDCs, in order to reinvigorate the cancer-immunity cycle.<h4>Methods</h4>In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)<sup>+</sup> myDCs +/- CD141 (BDCA-3)<sup>+</sup> myDCs on day"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Intratumoral administration of CD1c (BDCA-1)<sup>+</sup> and CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial."],"pmcid":["PMC9486335"],"funding_grant_id":["N/A","11102","2016-128"],"pubmed_authors":["Awada G","Cras L","Neyns B","Schwarze JK","Tuyaerts S","Bagnall C","Tijtgat J","Van Riet I","Vasaturo A","Forsyth R","Dufait I"],"additional_accession":[]},"is_claimable":false,"name":"Intratumoral administration of CD1c (BDCA-1)<sup>+</sup> and CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.","description":"<h4>Background</h4>Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)<sup>+</sup> / CD141 (BDCA-3)<sup>+</sup> myDCs, in order to reinvigorate the cancer-immunity cycle.<h4>Methods</h4>In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)<sup>+</sup> myDCs +/- CD141 (BDCA-3)<sup>+</sup> myDCs on day","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-06-08T06:46:23.032Z","creation":"2026-06-08T03:13:49.734Z"},"accession":"S-EPMC9486335","cross_references":{"pubmed":["36113895"],"doi":["10.1136/jitc-2022-005141"]}}